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Abstract 
The therapeutic potential of cannabinoids has been truly constrained heretofore 
due to their strong psychoactive effects and their high lipophilicity. In this context, 
precisely due to the lack of psychoactive properties, cannabidiol (CBD), the second 
major component of Cannabis sativa, arises as the phytocannabinoid with the most 
auspicious therapeutic potential. Hence, the incorporation of CBD in lipid nanocapsules 
(LNCs) will contribute to overcome the dosing problems associated with cannabinoids. 
Herein, we have prepared LNCs decorated and loaded with CBD for glioma 
therapy and screened in vitro their critical parameters. On the one hand, we have 
encapsulated CBD into the oily core of LNCs to test their in vitro efficacy as extended-
release carriers against the human glioblastoma cell line U373MG. The in vitro 
antitumor effect was highly dependent on the size of LNCs due to its pivotal role in the 
extent of CBD release. Effectively, a comparison between two differently-sized LNCs 
(namely, 20-nm and 50-nm sized carriers) showed that the smaller LNCs reduced by 
3.0-fold the IC50 value of their 50-nm sized counterparts. On the other hand, to explore 
the potential of this phytocannabinoid to target any of the cannabinoid receptors 
overexpressed in glioma cells, we decorated the LNCs with CBD. This functionalization 
strategy enhanced the in vitro glioma targeting by 3.4-fold in comparison with their 
equally-sized undecorated counterparts. Lastly, the combination of CBD-loading with 
CBD-functionalization further reduced the IC50 values. Hence, the potential of these two 
strategies of CBD incorporation into LNCs deserves subsequent in vivo evaluation. 
Keywords 
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1. Introduction 
Cannabis sativa is an herbaceous plant that contains over one hundred distinct 
pharmacologically-active terpenophenols that are produced in its glandular trichomes 
[1]. These compounds are known as phytocannabinoids since they chiefly exert their 
pharmacological effect on cannabinoid receptors. Other two types of cannabinoids are 
currently acknowledged: endocannabinoids, produced naturally by animals and 
humans, and synthetic cannabidomimetics.  
Various cannabinoids produce strong psychoactive effects, which have truly 
constrained their therapeutic potential. As a proof of it, the marketing authorization of 
rimonabant, a synthetic cannabidomimetic that had been approved as anorectic for 
obese patients, was withdrawn in 2009 due to its severe psychiatric side effects. 
Fortunately, cannabidiol (CBD), the second major component of Cannabis sativa, with 
the tetrahydrofuran ring cleaved, is devoid of psychoactive properties. Precisely due to 
this lack of psychoactive effects, CBD is doubtless the most auspicious 
phytocannabinoid for the treatment of various pathologies, namely inflammatory and 
neurodegenerative diseases, mental disorders, neuropathic pain, epilepsy and cancer 
[2]. In the latter case, apart from palliating cancer-related symptoms (such as nausea, 
pain or anorexia), CBD has been reported to promote apoptotic cancer cell death 
through the production of reactive oxygen species, to impair tumor angiogenesis and to 
reduce cell migration that ultimately accounts for metastasis [3-5]. Particularly, the 
expression of different receptors to which the phytocannabinoids bind is increased in 
glioma (cannabinoid receptors 1 and 2 (CB1 and CB2) [6] and transient potential 
vanilloid receptor type 2 (TRPV2) [7]). Accordingly, activation of these receptors by 
CBD induced apoptosis of glioma cells, while no effects were observed in normal 
human astrocytes [7, 8]. 
Glioblastomas are the most prevalent and aggressive type of glioma (classified 
as the highest malignancy grade of gliomas by the World Health Organisation due to 
their high proliferative potential and invasiveness) [9]. Since the current standard of 
care of glioblastoma remains questionable, with a poor median survival of 14.6 months 
and a 2-year survival rate of 26.5% [10], CBD can serve to widen the therapeutic 
armamentarium for the treatment of malignant brain tumors thanks to its synergistic 
effects with the currently available chemo and radiotherapy [11]. As a proof of it, CBD 
has already reached the clinical trials stage in combination with chemo and/or 
radiotherapy for patients with glioblastoma (NCT01812616, NCT01812603, 
NCT03246113, NCT03529448, NCT03607643 and NCT03687034). 
Nonetheless, the high lipophilicity of cannabinoids, including CBD, has also 
hampered their therapeutic potential. In this context, these substances can take great 
advantage of nanomedicine-based formulation strategies. Consistently, several studies 
on nanocarriers encapsulating the different kinds of cannabinoids (phytocannabinoids 
[12-14], cannabidomimetics [15-18], and endocannabinoids [19]) have started being 
published with distinct therapeutic purposes. Notwithstanding that for cannabinoids to 
achieve high translational impact they should be devoid of psychoactive effects, the 
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focus so far has been mainly put on the encapsulation of 9-delta-tetrahydrocannabinol 
(Δ9-THC) and its analogues. 
Herein, we develop monodisperse lipid nanocapsules (LNCs) as biocompatible 
and biodegradable carriers for CBD, the major non-psychotropic phytocannabinoid. 
LNCs are prepared by the energetically efficient phase inversion temperature (PIT) 
method. We encapsulate CBD into the oily core of LNCs at high drug loading, under 
the assumption that it would help overcome classical formulation issues linked to 
cannabinoids and attain a platform for its prolonged release after administration. Their 
in vitro efficacy against the human glioblastoma cell line U373MG is evaluated by 
means of cell viability experiments. The role played by the size of LNCs in CBD release 
and cytotoxicity is likewise thoroughly explored. Moreover, we evaluate the possibilities 
of this cannabinoid to target any of the cannabinoid receptors overexpressed in glioma 
cells as aforementioned. To this end, we develop a functionalization strategy of LNCs 
with CBD wherewith subsequently conduct uptake experiments on the same human 
glioblastoma cell line to evidence the potential targeting efficiency of this strategy. 
2. Materials and methods 
2.1. Materials 
Labrafac® lipophile WL 1349 (caprylic-capric acid triglycerides) was kindly 
supplied by Gattefossé. Kolliphor® HS15 (C18E15 polyethylene glycol (15) 12-
hydroxystearate) was a gift from BASF. Lipoid® S75 (soybean lecithin with 70% of 
phosphatidylcholine) was supplied by Lipoid-Gmbh. NaCl was purchased from 
Panreac. De-ionized water was obtained from a MilliQ® Purification System. The 
fluorescent dye 3,3'-dioctadecyloxacarbocyanine perchlorate (DiO) was purchased 
from Invitrogen Molecular Probes. Cannabidiol (CBD) was provided by THC-Pharma. 
Methanol, acetonitrile and tetrahydrofuran HPLC grade were purchased from Fisher 
Scientific. Amicon® Ultra 15 mL Centrifugal Filters (MWCO: 10 kDa) were supplied by 
Merck Millipore. Dulbecco’s Modified Eagle Medium (DMEM) and penicillin-
streptomycin (10,000 U/mL) were provided by Gibco. Fetal bovine serum (FBS) was 
supplied by Biowest. Hank’s Balanced Salt Solution (HBSS), 3-(4,5-dimethyl-2-
thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT), dimethyl-sulfoxide (DMSO) and 
sterile Nunc Lab-Tek® chamber slides (8 wells, Permanox® slide, 0.8 cm2/well) were 
purchased from Sigma-Aldrich. Vectashield® mounting medium with DAPI (H-1200) 
was provided by Vector Laboratories. 
2.2. Cell line 
The human glioblastoma U373MG cells were cultured in DMEM medium 
supplemented with 10% FBS, 100 U/mL penicillin and 100 μg/mL streptomycin at 37ºC  
in a humidified atmosphere containing 5% CO2. For all experiments, cells between 
passage 15 and 25 were used. 
2.3. Preparation of LNCs 
2.3.1. Blank LNCs  
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LNCs were prepared by the PIT method. Succinctly, Labrafac® WL 1349, 
Kolliphor® HS15, Lipoid® S75, NaCl and water were mixed under magnetic stirring and 
progressively heated over the phase inversion temperature of the system. 
Subsequently, the mixture was gradually cooled down until the phase inversion 
temperature was reached. Then, a sudden quench with cold water (5 mL) was 
performed to obtain the final suspension of LNCs. By varying the relative proportions of 
the excipients, formulations of blank LNCs in different sizes were prepared. 
2.3.2. CBD-loaded LNCs 
CBD was encapsulated in LNCs for in vitro efficacy experiments. To prepare the 
CBD-loaded LNCs, the cannabinoid was firstly dissolved in the oily phase that 
constitutes the core of the LNCs at a concentration of 15 % CBD/ Labrafac® WL1349 
(w/w). Then, the remaining excipients were added and progressively heated and 
cooled down around the phase inversion temperature as indicated in 2.3.1. 
2.3.3. Fluorescently-labeled LNCs 
The fluorescent dye DiO was encapsulated in LNCs for particle tracking 
purposes in in vitro experiments. To prepare the dye-loaded LNCs, the fluorescent dye 
was firstly dissolved in the oily phase that constitutes the core of the LNCs at a weight 
ratio of 15 mg of dye/ g of Labrafac® WL1349. Then, the remaining excipients were 
added and progressively heated and cooled down around the phase inversion 
temperature as indicated in 2.3.1. 
2.3.4. Functionalization of LNCs with CBD  
Pre-formed blank LNCs were incubated with a CBD solution to ultimately obtain 
functionalized LNCs at two different concentrations of CBD (10 mg/mL in a 1:4 (v/v) 
ratio for a final CBD concentration of 2.5 mg/mL, and 15 mg/mL in a 1:3 (v/v) ratio for a 
final CBD concentration of 5 mg/mL, respectively). The mixture was gently stirred 
overnight until complete solvent evaporation. The contribution of the solvent itself to the 
size distribution of LNCs was ruled out by incubating LNCs with pure solvent. Similarly, 
fluorescently-labeled and CBD-loaded LNCs were also functionalized with CBD at the 
higher concentration (5 mg/mL). 
The detailed excipient weight for each group of LNCs is shown in Table 1: blank 
LNCs (F1-F3), CBD-loaded LNCs (F4-F6), CBD-functionalized LNCs (2.5 mg/mL –F7-
F9- and 5 mg/mL –F10-F12), fluorescently-labeled LNCs (F13-F16) and CBD-
functionalized-CBD-loaded LNCs (F17 and F18). 
2.4. Characterization of LNCs 
2.4.1. Size distribution and zeta potential 
The average volume diameter and polydispersity index (PdI) of each 
formulation were measured by dynamic light scattering (DLS) using a Microtrac® 
Zetatrac™ Analyzer (Microtrac Inc., USA). Measurements were done in triplicate. The 
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zeta potential of the different formulations of LNCs was measured by means of a 
Zetasizer Nano ZS (Malvern Instruments). 
2.4.2. Morphological examination of LNCs 
The morphological examination of LNCs was performed by transmission 
electron microscopy (TEM). TEM images were taken on a T20-FEI Tecnai thermionic 
microscope at the Advanced Microscopy Laboratory, LMA, (Zaragoza, Spain). To 
prepare the samples for TEM, 20 μl of lipid nanocapsule suspension was dropped on a 
carbon copper grid (200 mesh), negatively stained with phosphotungstic acid and dried 
at room temperature. The microscope was operated at an acceleration voltage of 200 
kV. 
2.4.3. Incorporation efficiency and drug content 
The incorporation efficiency (IE) and drug content (DC) of CBD in the different 
formulations of LNCs were determined by high performance liquid chromatography 
(HPLC). The HPLC method was adapted from [20]. An Agilent 1200 Infinity HPLC 
system was utilized. A mixture of methanol: acetonitrile: water (52:30:18 v/v) at a flow 
rate of 1.8 mL/min was used as mobile phase. The analytical column was a reversed-
phase Mediterranea Sea® C18 (5μm 15 x 0,46 cm) (Teknokroma®). The retention time 
of CBD was 5 minutes. 
The incorporation efficiency was calculated using equation 1, whereas the drug 
content was calculated using equation 2:  
      
                                 
                            
     (Equation 1) 
      
                                 
                             
     (Equation 2) 
where the amount of CBD associated with LNCs in each case was determined 
as the difference between the total amount of CBD in suspension derived from the lysis 
of LNCs with tetrahydrofuran (1:5 (v/v)) and the unassociated CBD filtered with 10 kDa 
Amicon® Centrifugal Filters (6000 rpm, 60 min). 
2.5. In vitro cytotoxicity 
Free CBD, CBD-loaded LNCs (F10 and F11) and CBD-functionalized CBD-
loaded LNCs (F17 and F18) were assessed for cytotoxicity against human 
glioblastoma U373MG cells using an MTT assay. Briefly, U373MG cells were seeded 
into 96-well plates at a density of 2 x 104 cells/well. After cells had been confluent for 
48 hours, they were treated with free CBD for 48 hours and with suspensions of LNCs 
(200 µL) for 48 and 96 hours. Then, the medium was removed and 60 µL of MTT 
solution (1 mg/mL) in complete DMEM were added to each well and incubated for 4 
hours. Afterwards, the media containing the MTT was removed and 100 µL of DMSO 
was added to each well. The plates were agitated for 10 minutes and the absorbance 
was measured at 570 nm using a microplate reader (Varioskan Flash, Thermo 
Scientific). Experiments were performed in triplicate at each time-point. For each 
formulation of CBD-loaded LNCs, U373MG cells treated with their blank counterparts 
served as control. Cell viability of each group was expressed as a percentage relative 
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to that of control. The half-maximal inhibitory concentration (IC50) was calculated in 
each case for comparison purposes. 
2.6. In vitro cellular uptake  
2.6.1 Uptake experiments evaluated by flow cytometry 
To quantitatively evaluate the glioma targeting ability of LNCs in vitro, U373MG 
cells were seeded into 6-well plates at a density of 2.5 x 105 cells/well. After cells had 
been confluent for 48 hours, the culture medium was replaced by DiO-labeled LNCs 
(F13-F16 at an equivalent dye concentration of 1.65 µg DiO/mL of suspension) 
suspended in complete DMEM (2 mL) wherewith cells were incubated for 24 hours. 
Then, cells were rinsed with HBSS, trypsinized and finally resuspended in 0.3 mL of 
HBSS. The fluorescence intensity of cells treated with fluorescent-LNCs was analyzed 
with a flow cytometer (Beckman Coulter Epics XL). Experiments were performed in 
triplicate. U373MG cells treated with blank LNCs served as control. Cellular uptake of 
each group was expressed as fold-increase in mean fluorescence relative to that of 
control after correction for the different amount of dye per individual LNC in each 
formulation. 
2.6.2. Uptake experiments evaluated by confocal microscopy 
To qualitatively illustrate the glioma targeting ability of LNCs in vitro, U373MG 
cells were seeded into chamber slides at a density of 2 x 104 cells/well. After cells had 
been confluent for 48 hours, the culture medium was replaced by undecorated or CBD-
functionalized DiO-labeled LNCs at an equivalent dye concentration of 1.65 µg DiO/mL 
suspended in complete DMEM (0.35 mL) wherewith cells were incubated for 24 hours. 
Then, cells were rinsed with HBSS and mounted with Vectashield® with DAPI mounting 
medium. The cells were then observed with a confocal microscope (Leica TCS SP5, 
405 nm for DAPI, 488 nm for DiO). U373MG cells treated with blank LNCs served as 
control. 
2.7. Statistical analysis 
All experiments were done in triplicate and all data are expressed as mean ± 
SEM. Unpaired Student’s t test was used for two-group analysis. Statistical significance 
was fixed as *:p<0.05, **:p<0.01,***:p<0.001. All the data were analyzed using the 
GraphPad Prism 7 software. 
3. Results and discussion 
Blank monodisperse LNCs were obtained by the PIT method in different sizes 
by varying the relative proportion of excipients as detailed in Table 1 (F1-F3). In 
formulations F4-F6, CBD was included in the formulation procedure as drug payload 
dissolved in the oily phase of the core of the capsules at a concentration of 15 % 
CBD/Labrafac® WL1349 (w/w). The choice of the oily phase was based on the 
solubility of CBD to easily achieve both high encapsulation efficiencies and drug 
loading. In this regard, whereas the authors that tried to encapsulate distinct 
cannabinoids in polymer nanoparticles only achieved encapsulation efficiencies around 
70% [15, 16, 21], those studies that utilized lipid-based carriers exhibited values above 
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90% [17, 22]. This comparison has been corroborated by Durán-Lobato et al [23]. 
Unlike these authors, we utilized a low-energy method to prepare monodisperse lipid 
carriers in smaller sizes. The high incorporation efficiencies reported herein (Table 2) 
are in agreement with those values achieved for the incorporation of drug substances 
with similar log P values into analogous carriers [24, 25] and significantly higher than 
those obtained with less lipophilic drug substances, as etoposide with a log P= 1.1 only 
achieved a 56% of incorporation efficiency [26]. However, whereas these authors 
achieved at best a drug loading of 1.5% [25], we have utilized herein much higher 
percentages of CBD content (Table 2, F4-F6).  
According to our size distribution measurements, for all these CBD-loaded 
formulations (F4-F6) there was a statistically significant increase in particle size that 
progressively augmented with the initial size of blank LNCs (Fig. 1a, p<0.05). These 
results are positively correlated with the respective percentage of drug loading that 
represented CBD in each case, which was the highest for the biggest LNCs (9.78%) 
and the lowest for the smallest ones (4.30%). Interestingly, the CBD loading in the oily 
core did not significantly alter the polydispersity index (PdI) in comparison with blank 
LNCs (Fig 1b, p>0.05). Moreover, in agreement with the hypothesized encapsulation 
within the oily core, no changes in the zeta potential profiles were evidenced (Fig. 1c-
h). Indeed, values close to neutrality with high profile width were obtained in all cases, 
as it might be expected from a shell made of a complex mixture of poly (ethoxylated) 
surfactants (Kolliphor® HS15). Consistently, the width of the zeta potential distribution 
was progressively reduced with a decrease in the surfactant percentage (from the 
smallest (Fig. 1 c-d) to the biggest LNCs (Fig. 1 g-h)). 
Moreover, to explore the potential of this phytocannabinoid to target any of the 
cannabinoid receptors overexpressed in glioma cells, we have developed a 
functionalization strategy of LNCs with CBD on their surface. This strategy consisted in 
the incubation of pre-formed LNCs with a CBD solution to obtain functionalized LNCs 
at two different concentrations of CBD (2.5 and 5 mg/mL, respectively). The incubation 
of LNCs with pure solvent did not contribute to any increase in particle size (data not 
shown). Hence, all changes observed in the characterization of LNCs were attributed to 
the cannabinoid itself. We followed an analogous procedure to the one utilized by other 
authors to incorporate novel targeting peptides on the surface of LNCs [27, 28]. 
However, whereas these authors only achieved 48.3% adsorption efficiency, we report 
herein higher incorporation efficiencies for CBD-functionalization (Table 2). These 
results could be explained by the lower aqueous solubility of CBD than that of peptides, 
which ultimately favors its adsorption to the amphiphilic surfactant interface. According 
to the size distribution measurements, the functionalization with CBD significantly 
increased the particle size of blank LNCs (Fig. 2a, p<0.05). This increase in average 
volume diameter is noticeably higher than the increase observed for CBD-loaded LNCs 
(F4-F6), even if the percentage of drug content is much lower in the case of CBD-
functionalized LNCs (Table 2). These results supported that CBD should be placed in a 
distinct location than the capsule core. Indeed, the increase in volume diameter 
followed an inverse size-related pattern: the greatest percentage of size increase was 
observed with the smallest LNCs (75%) and vice versa (33% increase for medium-
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sized LNCs and 16% increase for the biggest LNCs). The higher specific surface area 
and the higher surfactant density at the particle interface of the smallest LNCs could 
account for this trend observed upon CBD functionalization. Noticeably, the 
polydispersity index in the smallest and medium-sized LNCs was significantly 
increased in comparison with their blank counterparts (Fig. 2b, p<0.01), which did not 
occur when the CBD was incorporated dissolved in the oily core. Furthermore, in 
agreement with the hypothesized superficial location of CBD, the zeta potential profiles 
were remarkably smoothed in comparison to the ones previously obtained both for 
blank and CBD-loaded LNCs (Fig. 2 c-h). These profiles are consistent with a shell 
dominated by a single entity instead of the former mixture of poly (ethoxylated) 
surfactants and, accordingly, were steadily sharpened with an increase in CBD content 
in the final formulation from 2.5 mg/mL (Fig. 2 c, e, g) to 5 mg/mL (Fig. 2 d, f, h). 
The different formulations of LNCs were visualized through transmission 
electron microscopy (TEM). Interestingly, TEM images served to evidence the 
spherical morphology of LNCs (Fig. 3). In no case did this geometry significantly vary 
upon incorporation of CBD. Moreover, the previous analysis of size distribution of the 
different formulations based on DLS data was highly corroborated with particle sizes 
observed through TEM. 
Altogether, our results highlight that LNCs arise as biocompatible and 
biodegradable carriers for CBD, the main non-psychotropic phytocannabinoid, which 
will doubtless contribute to palliate the technological constraints traditionally associated 
with cannabinoids due to their high lipophilicity [29]. In particular, we have 
encapsulated CBD into the oily core of LNCs at high drug loading to attain a prolonged-
release platform for this cannabinoid wherewith we will test their in vitro efficacy against 
the human glioblastoma U373MG cell line. Moreover, we have decorated the surface of 
LNCs with CBD wherewith subsequently conduct uptake experiments on the same 
human glioblastoma cell line to explore the possibilities of this cannabinoid to target in 
vitro any of the cannabinoid receptors overexpressed in glioma cells. 
The fact of having obtained two distinct delivery systems with the CBD located 
either in the oily core or on the surface of the LNCs by varying the formulation 
procedure seems to refute the drop tensiometry experiments performed by some 
authors to elicit the disposition of a particular cargo within a core-shell carrier on the 
grounds of the monitored surface tension between the aqueous and oily phases upon 
addition of the cargo [27, 30]. These studies focus on the interactions with the aqueous 
and oily phases but overlook the role played by the surfactant shell in the cargo 
incorporation. Moreover, they underestimate the potential influence of the incorporation 
procedure on the final disposition of the drug substance within the carrier. 
Furthermore, both untargeted and CBD-decorated fluorescently-labeled LNCs 
were developed for in vitro particle tracking purposes (F13-F16) and CBD-decorated-
CBD-loaded LNCs were obtained to evidence if the CBD-decoration could enhance the 
in vitro cytoxicity of CBD-loaded LNCs. As shown in Figure 4a, after loading F1 and F2 
with fluorescent dyes, we obtained analogously-sized LNCs: 20 nm (F13) and 40 nm 
(F14). However, the decoration of dye-loaded LNCs with CBD increased the particle 
size to 40 nm (F15) and 60 nm (F16), respectively. Similarly, the functionalization with 
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CBD of CBD-loaded LNCs (F4 and F5) significantly increased the average volume 
diameter to 40 nm (F17) and 60 nm (F18), respectively (Figure 4a). As observed with 
blank LNCs, the polydispersity index invariably increased after CBD decoration in 
comparison with their untargeted counterparts (Figure 4b). 
In cytotoxicity experiments, the role played by particle size in the efficacy of 
LNCs as extended-release carriers for CBD has been evaluated with 20 nm and 50 
nm-sized CBD-loaded LNCs (namely, F4 and F5). 
Free CBD and the LNCs loaded with CBD within their oily core were tested for 
in vitro efficacy against the human glioblastoma U373 MG cell line by the MTT assay. 
Blank LNCs were used as controls for their CBD-loaded counterparts. Remarkably, 
blank LNCs did not show any significant cytotoxicity against the U373MG cell line 
within the concentration range tested (cell viability above 70% versus untreated cells 
according to the ISO 10993-5 Biological evaluation of medical devices, Part 5: Tests for 
in vitro cytotoxicity). Hence, all changes observed in the percentage of cell viability 
were attributed to the extent of CBD released from the LNCs at each time point. As 
other authors have previously reported that the total drug loading might play a role in 
the relative drug release from LNCs [31], we have normalized herein the concentration 
at which the drug is firstly dissolved in the oily phase (namely, 15 % of CBD/ Labrafac® 
WL1349 (w/w)) so that no differences in the partition gradient to the culture medium 
can be observed among drug-loaded formulations that could ultimately account for 
different release patterns. In this way, differences in the extent of CBD released will be 
solely dependent on the distinct release profiles from differently-sized LNCs. 
Both free CBD and CBD-loaded LNCs reduced the viability of U373MG cells in 
a concentration-dependent manner, demonstrating thereby the in vitro antitumor effect 
of CBD against human glioblastoma. As shown in Table 3, free CBD (IC50 = 29.1 μM) 
exhibited an evident anti-proliferative effect against the U373MG cells, with an IC50 
value in agreement with those values reported in [32]. In all cases, the inclusion of CBD 
within the core of the LNCs considerably increased the IC50 value achieved with free 
CBD. These results are explained by the fact that free CBD is readily available to exert 
its cytotoxic effect on glioma cells, whereas encapsulated CBD must be released from 
the oily core of LNCs firstly, a process that can be prolonged over longer periods. Other 
authors have recently observed analogous trends for other combinations of drug 
substances and carriers [33-35]. 
In particular, we report herein that the size of LNCs plays a pivotal role in the 
extent of CBD release. In this regard, based on a 48 hours treatment period, the IC50 of 
20 nm-sized LNCs (F4) outperformed the IC50 value of 50-nm sized LNCs (F5): 202.6 
μM vs 615.4 μM, respectively (Figure 5, Table 3). This finding highlights the distinct 
release patterns as a function of particle size. Moreover, we further evaluated the 
cytotoxic effect of these formulations over 96 hours to demonstrate if LNCs could serve 
as efficient prolonged-release carriers. Effectively, both formulations continued to 
release CBD from their oily cores and the IC50 values were consequently reduced with 
a longer treatment period (129.1 μM vs 202.6 μM for F4 and 375.4 μM vs 615.4 μM for 
F5). As occurred on the 48 hours treatment period, the IC50 values were lower for the 
smaller LNCs (129.1 μM vs 375.4 μM). Noticeably, regardless the incubation period, 20 
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nm-sized CBD-loaded LNCs (F4) achieved a 3-fold reduction in IC50 in comparison with 
50-nm sized CBD-loaded LNCs (F5) (Table 3). 
So as to determine their in vitro glioma targeting ability, different formulations of 
fluorescently-labeled LNCs at an equivalent dye concentration of 1.65 µg DiO/mL of 
suspension were tested on the human glioblastoma U373MG cell line by flow 
cytometry (Figure 6). In uptake experiments, the role played by particle size in the 
glioma targeting properties has been assessed separately in non-decorated and in 
CBD-decorated dye-loaded LNCs (namely, F13 vs F14 and F15 vs F16) and, on the 
other hand, the influence of CBD-decoration in glioma targeting has been evaluated for 
equally-sized LNCs (namely, F14 vs F15). 
Overall, all tested formulations were efficiently internalized by the human 
malignant glioma cells, with more than 99% of positive cells in all cases. On the one 
hand, the influence of particle size on the extent of cellular uptake by the human 
glioblastoma cell line was evaluated with the purpose of determining the most 
auspicious features that the ideal carrier should accomplish to move forward to in vivo 
studies. This influence was evaluated both in the absence (F13 vs F14) and in the 
presence of the cannabinoid on the surface of the LNCs (F15 vs F16). In this regard, 
the measured fluorescence intensities allowed us to draw a consistent comparison of 
the role played by particle size for both undecorated LNCs (Figure 6a, p<0.05) and 
CBD-functionalized LNCs (Figure 6b, p<0.001): a decrease in volume diameter yielded 
an increase in in vitro uptake by malignant glioma cells. 
On the other hand, the role played by the functionalization with CBD in the 
extent of in vitro cellular uptake was also quantitatively evaluated. The functionalization 
with CBD significantly enhanced the in vitro glioma targeting properties of LNCs, as it 
was concluded from a comparison of equally sized non-decorated and CBD-
functionalized LNCs (F14 vs F15, Figure 6c, p<0.001). Altogether, the highest glioma 
targeting ability was achieved with the smallest cannabinoid-decorated LNC 
formulation (F15). 
We have reported herein that the functionalization of LNCs with CBD enhanced 
the in vitro glioma targeting properties by 3.4-fold in comparison with their equally-sized 
undecorated counterparts. These auspicious in vitro glioma-targeting properties 
demonstrated for the CBD-functionalization strategy are in the same order of 
magnitude than those observed with other glioma targeting moieties [36, 37]. For 
instance, the aptamer AS1411 that binds to nucleolin, a protein overexpressed in highly 
proliferative cells yielded a 3-fold increase in in vitro glioma-targeting properties of poly 
glutamylglutamine nanoconjugates when tested in the human glioblastoma U87MG cell 
line [36]. With this same cell line, angiopep-2 (a targeting moiety currently in clinical 
trials for different brain tumor conditions that promotes receptor-mediated transcytosis 
through the low density lipoprotein receptor LRP1) enhanced the cellular uptake of poly 
(lactic-co-glycolic) acid nanoparticles by 3.6-fold [37]. Unlike angiopep-2, the non-
peptide nature of CBD makes it less prone to cause immunogenicity.  
Interestingly, CBD performed better than other tested glioma-targeting moieties. 
In this regard, two different ligands of the transferrin receptor, highly expressed in 
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glioma cells, yielded a 1.73-fold and 2.28-fold increase (for transferrin [38] and T7 
peptide [39], respectively) in the cellular uptake of liposomes and core-shell 
nanoparticles into the C6 and U87MG cell lines. Analogously, mannose, utilized as 
ligand targeting the glucose transporter GLUT1, only achieved a 1.18-fold increase in 
cellular uptake of liposomes into the rat glioma C6 cell line [38]. 
Concomitantly, we have reported herein that a reduction in particle size of LNCs 
enhanced the cellular uptake by 3.0-fold for undecorated LNCs and 3.5-fold for CBD-
decorated LNCs. In this regard, it is worth mentioning that none of the aforementioned 
studies evaluated the role played by particle size in the internalization extent of 
nanocarriers by glioma cells. 
Moreover, the in vitro glioma targeting ability of LNCs was further analyzed 
qualitatively by confocal microscopy. As shown in Figure 7, both undecorated and 
CBD-functionalized LNCs were efficiently internalized by U373MG cells. The images 
taken by confocal microscopy consistently demonstrated a significantly higher glioma 
targeting effect for CBD-functionalized LNCs. The 3D reconstruction from the Z-stack 
projections corroborated that the fluorescent signal from LNCs localized in the 
intracellular compartment of the human glioblastoma cells, preferentially in the 
perinuclear region (Figure 8). A 3D video reconstruction performed by means of the 
LAS X software further supporting the perinuclear localization is available as 
supplementary material. 
Given the enhancement in in vitro glioma targeting properties of the CBD-
decorated LNCs evidenced by flow cytometry and confocal microscopy, we tested if the 
functionalization of CBD-loaded LNCs with CBD, with the ensuing enhanced 
internalization extent, could further reduce the IC50 values achieved for their 
undecorated counterparts. As shown in Figure 9, CBD-functionalized CBD-loaded 
LNCs outperformed the cytotoxicity of CBD-loaded LNCs following 48 hours treatment 
(namely, 158.6 μM vs 202.6 μM for F17 and F4; and 513.2 μM vs 615.4 μM for F18 and 
F5, respectively, Table 3). These results can be accounted for by the differences in the 
drug release rate as a function of the distinct location of the CBD in each formulation. 
Whereas CBD-decorated LNCs exhibit part of the cannabinoid on their surface, and 
hence more prone to faster release within glioma cells, undecorated CBD-loaded LNCs 
have the totality of the drug encapsulated within the oily core, wherein CBD has higher 
solubility and calls for a longer distance for diffusion. 
Altogether, results from cytotoxicity and uptake experiments are highly 
interrelated. On the one hand, a decrease in volume diameter yields a reduction in the 
IC50 values in cytotoxicity experiments due to the faster CBD release and an increase 
in the in vitro uptake by glioblastoma cells. Hence, the cellular uptake and the drug 
release rate that ultimately leads to greater cytotoxicity against glioma cells can be 
tailored by varying the particle size of LNCs. On the other hand, the functionalization 
with CBD further reduced the IC50 values of CBD-loaded LNCs and enhanced the in 
vitro glioma targeting properties of LNCs. 
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These LNCs decorated and loaded with CBD offer great promise as targeted 
prolonged release carriers for glioma therapy. Both localized and systemic 
administration can be envisioned for these carriers [40]. On the one hand, localized 
delivery (such as convection enhanced delivery) could be used to mechanically bypass 
the blood-brain barrier (BBB) and directly deliver the drug carriers to the brain tissue, 
where they will profit from the active targeting strategy with CBD to preferentially bind 
to the receptors overexpressed on the brain tumor cells. On the other hand, should the 
herein-described glioma targeting strategy be combined with a further targeting 
strategy to efficiently cross the brain endothelium, glioma therapy with these LNCs 
could be accomplished following intravenous administration. 
Importantly, the high CBD load achieved with LNCs may serve to meet the dose 
requirements reported in the first clinical trials that use CBD as adjuvant therapy for 
patients with glioblastoma. In this respect, in the NCT01812603 clinical trial 
glioblastoma patients received a maximum daily dose of 30 mg of CBD (in combination 
with a maximum daily dose of 32.4 mg of THC and dose-intense temozolomide). 
Importantly, this dosing regimen including cannabinoids served to nearly double both 
the 1-year survival rate and the median survival time [41]. Similarly, the recent 
NCT03529448 clinical trial has been designed so that patients are given a maximum 
daily dose of 40 mf of CBD (in combination with a maximum daily dose of 40 mg of 
THC along with temozolomide and radiotherapy within the STUPP regime). Even more 
recently, the NCT03607643 clinical trial has been conceived to test the potential of 
CBD as a single cannabinoid as adjuvant therapy for glioblastoma. Hence, devoid of 
safety concerns associated with psychoactive effects of THC, this study will increase 
the CBD doses up to 200 mg daily (a dose requirement that could still presumably be 
met with encapsulation into the LNC core). 
Furthermore, the extended CBD release profile observed for CBD-loaded LNCs 
could greatly improve the dosing regimens in clinical trials, as CBD-loaded LNCs could 
significantly reduce the number of administrations required (which are, respectively in 
the aforesaid clinical trials, up to 12 times per day in NCT01812603, three-times a day 
in NCT03529448 or twice daily in NCT03607643). 
Moreover, the glioma targeting properties of the CBD-decoration described 
herein are not exclusive for encapsulation of cannabinoids. Indeed, other antitumor 
agents traditionally included in chemotherapy protocols (such as temozolomide) can 
profit from the inclusion into CBD-decorated LNCs for glioma therapy. 
4. Conclusions 
Although cannabinoids show auspicious pharmacological properties, their 
therapeutic potential has not yet been widely explored due to two main issues: their 
strong psychoactive effects and their high lipophilicity. Hence, precisely due to their 
lack of psychoactive properties, CBD can take great advantage of nanomedicine-based 
formulation strategies for the treatment of various pathologies. In particular, CBD has 
been reported to not only palliate cancer-related symptoms (such as nausea, pain or 
anorexia) but also promote apoptotic cancer cell death through the production of 
reactive oxygen species, impair tumor angiogenesis and reduce cell migration. 
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Therefore, CBD could serve to widen the therapeutic armamentarium for the treatment 
of malignant brain tumors thanks to its synergistic effects with the currently available 
treatments and to this end, we have encapsulated CBD into the oily core of LNCs at 
high drug loading and evaluated their in vitro efficacy as prolonged-release carriers 
against the human glioblastoma cell line U373MG. The in vitro antitumor effect of CBD 
against human glioblastoma has been confirmed and the size of LNCs has been 
evidenced to play a pivotal role in the extent of CBD release: 20 nm-sized LNCs 
reduced by 3.0-fold the IC50 value of 50-nm sized LNCs. 
Moreover, since the expression of different receptors to which the cannabinoids 
bind is increased in glioma, CBD could actively target glioma cells. Therefore, we have 
functionalized LNCs with CBD and evaluated their in vitro glioma targeting ability with 
the same human glioblastoma cell line. The functionalization of LNCs with CBD 
enhanced the in vitro glioma targeting properties by 3.4-fold in comparison with their 
equally-sized undecorated counterparts. These glioma-targeting properties equal the 
enhancements obtained with some other targeting moieties such as the AS1411 and 
angiopep-2 (the latter has already reached the clinical trials stage) and even 
outperform those achieved with transferrin and mannose.  
Lastly, provided that the functionalization with CBD enhances the in vitro glioma 
targeting, we further evaluated if the functionalization of CBD-loaded LNCs with CBD 
could further reduced the IC50 values achieved for their undecorated counterparts. In all 
cases, CBD-functionalized CBD-loaded LNCs outperformed the cytotoxicity of CBD-
loaded LNCs following 48 hours treatment. 
Taken together, our results offer great promise for subsequent in vivo 
evaluation of LNCs loaded and decorated with CBD. 
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Table 1: Detailed excipient weight (in mg) for each formulation of LNC in final 
suspension. 
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LNC formulation IE (%) DC (%) 
F4 96.75 ± 1.45 4.30 ± 0.07 
F5 96.43 ± 3.25 7.66 ± 0.30 
F6 95.38 ± 1.25 9.78 ± 0.13 
F7 94.17 ± 1.54 0.76 ± 0.02 
F8 98.91 ± 2.75 1.16 ± 0.02 
F9 95.22 ± 0.78 1.21 ± 0.01 
F10 96.99 ± 2.58 1.55 ± 0.07 
F11 95.97 ± 4.72 2.17 ± 0.06 
F12 98.61 ± 2.02 2.51 ± 0.06 
Table 2: Incorporation efficiencies (IE) and drug content (DC) of the different 
LNCs following the distinct strategies to incorporate CBD discussed in the text. 
Formulation and time IC50 (μM) 
Free CBD 48h 29.1 
F4 48h 202.6 
F4 96h 129.1 
F5 48h 615.4 
F5 96h 375.4 
F17 48h 158.6 
F18 48h 513.2 
Table 3: IC50 values of free CBD and the different CBD-loaded LNCs against 
the U373MG cell line. 
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